Ⓐ
PeptiBrief
Evidence Library
human_metabolic_physiology_study · 2012

Xenin-25 amplifies GIP-mediated insulin secretion in humans with normal and impaired glucose tolerance but not type 2 diabetes

Wice BM|Reeds DN|Tran HD|Crimmins DL|Patterson BW|Dunai J|Wallendorf MJ|Ladenson JH|Villareal DT|Polonsky KS · Diabetes
moderatePMID · 22522617Verified
View source
Plain-English summary

Xenin-25 enhanced GIP-related insulin secretion in people without established type 2 diabetes.

Population
Adults with normal glucose tolerance, impaired glucose tolerance or type 2 diabetes
Intervention
Xenin-25 with glucose and GIP stimulation
Outcomes measured
Insulin secretion|Glucose|Glucagon|Gastrointestinal effects
Key findings
Supported a glucose-tolerance-dependent interaction between xenin and GIP.
Limitations
Small physiology study|Short infusion|No long-term metabolic outcomes
Risk of bias
Moderate for treatment claims; useful for human target engagement.
Citation
Wice BM|Reeds DN|Tran HD|Crimmins DL|Patterson BW|Dunai J|Wallendorf MJ|Ladenson JH|Villareal DT|Polonsky KS (2012). Xenin-25 amplifies GIP-mediated insulin secretion in humans with normal and impaired glucose tolerance but not type 2 diabetes. Diabetes
Linked peptides in the PeptiBrief database
ImportantPeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.